Precision base editing medicines
Founded by base editing inventor David Liu, Beam Therapeutics develops precision genetic medicines using base editing technology. Base editors can make single-letter changes to DNA without creating double-strand breaks.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| BEAM-101 | Sickle Cell Disease | Phase 1/2 | Base Editing |
| BEAM-302 | Alpha-1 Antitrypsin Deficiency | Phase 1 | Base Editing |
| BEAM-201 | T-ALL | Phase 1/2 | Base Editing |
A look at the publicly traded gene editing companies best positioned for 2026, from the first approved CRISPR therapy to next-generation platforms targeting cardiovascular disease and cancer.
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.
Three companies, three different gene editing technologies, three different investment theses. Here's how Intellia (CRISPR), Beam (base editing), and Prime Medicine (prime editing) compare as investments in 2026.